Skip to content or footer

CBC's Quirks & Quarks features AmacaThera Co-Founder Dr. Molly Shoichet

   Media Coverage

ICYMI: Thanks to CBC’s Quirks and Quarks for re-running this November 2020 interview with our co-founder, Dr. Molly Shoichet.

She spoke with Bob McDonald about winning the Gerhard Herzberg Canada Gold Medal and her research in hydrogel materials. AMT-143, our lead product, is grounded in this research and is currently approved for a Phase I clinical trial.

Listen to the interview or read the news story.

More Recent News

RB Cx Profile Amaca Thera Blog Thumbnail scaled

RBCx features AmacaThera’s journey

   Media Coverage

RBCx, the tech banking and investment arm of the Royal Bank of Canada, has featured AmacaThera’s drug development platform and start-up journey.
Read more

AmacaThera doses First In Human Study to Evaluate, AMT-143, for Non-opioid Treatment of Post-operative Pain

   Press Release

AmacaThera Inc, a clinical stage biotechnology company specializing in the development of advanced sustained release hydrogel formulations, has dosed its first human subject with AMT-143, the company's lead asset in non-opioid acute pain management. Read more

AmacaThera Closes Series A Extension to Advance Clinical Development of Long Acting, Localized, Non-Opioid Therapeutics to Improve Post-Surgery Patient Care

   Press Release

AmacaThera, a leader in the development of novel injectable, localized therapeutics based upon its AmacaGel delivery platform, announced the closing of a CAD$4.0 million financing round.Read more

See All Recent News
Amacathera Logo

AmacaThera is a clinical-stage biotechnology company transforming therapeutics to make a difference in patient health. Our unique, injectable hydrogel platform provides localized, sustained drug delivery to improve patient outcomes across multiple therapeutic areas, including post‑surgical pain management, cancer and other hard‑to‑reach target areas.

Contact Us

[email protected]
Offices & Phones